Key result
Aspirin and other antiplatelet agents may reduce the risk of vascular occlusion by blunting the early morning circadian surge in platelet aggregability that triggers acute thrombosis.
Why the study?
Does aspirin blunt short-term changes in platelet aggregability and reduce the circadian variation of acute thrombosis?
Does aspirin blunt short-term changes in platelet aggregability and reduce the circadian variation of acute thrombosis?
Aspirin's efficacy in reducing vascular occlusion risks may partly result from blunting the early morning surge in platelet aggregability.
The onset of several acute cardiovascular diseases occurs in a circadian pattern, with a peak incidence in the hours soon after awakening. This finding, coupled with laboratory data that confirm a surge in platelet activation during the early morning hours, suggests that acute changes in platelet aggregability may be an important trigger of thrombosis. Therefore, the efficacy of antiplatelet agents, such as aspirin, in reducing risks of vascular occlusion may result, at least in part, from a blunting of these short-term changes in platelet aggregability. In this review, clinical and laboratory evidence describing these cyclical changes is discussed, as is current evidence of the effects of aspirin on platelet function and the circadian variation of acute thrombosis.
No takes yet. Share an insight, caveat, or question.
Ridker et al. (1991) conducted a review in Acute cardiovascular diseases and acute thrombotic events. Aspirin and other antiplatelet agents was evaluated. Aspirin and other antiplatelet agents may reduce the risk of vascular occlusion by blunting the early morning circadian surge in platelet aggregability that triggers acute thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: